WHO Solidarity Trial Plus: An International Randomised Trial of Additional Treatments for COVID-19 in Hospitalised Patients Who Are All Receiving the Local Standard of Care in Nepal

Gyanwali et al., NCT05273242, NCT05273242, Dec 2022

Artemisinin

45th treatment shown to reduce risk in November 2022, now with p = 0.0066 from 3 studies, recognized in 13 countries.

Lower risk for recovery.

No treatment is 100% effective. Protocols combine treatments.

6,300+ studies for 210+ treatments. c19early.org

Meta Analysis

Estimated 400 patient artemisinin late treatment RCT with results not reported over 3 years after estimated completion.

2 artemisinin RCTs have results missing long after expected1,2
The trials report an estimated total of 1,366 patients.

Important missing comments or errors? Let us know.

1. Fowler et al., A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization), NCT04330690, clinicaltrials.gov/study/NCT04330690clinicaltrials.gov.

2. Gyanwali et al., WHO Solidarity Trial Plus: An International Randomised Trial of Additional Treatments for COVID-19 in Hospitalised Patients Who Are All Receiving the Local Standard of Care in Nepal, NCT05273242, clinicaltrials.gov/study/NCT05273242clinicaltrials.gov.

Gyanwali et al., 1 Dec 2022, Randomized Controlled Trial, Nepal, trial NCT05273242 (history). Contact: prgyawali654@gmail.com, clinicaltrialnepal@gmail.com, bideshbista@hotmail.com, pradptiwari@gmail.com, yubarajsharma@pahs.edu.np.

Late treatment
is less effective